These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32985068)

  • 1. N6-methyladenosine (m6A) RNA modification in cancer stem cells.
    Ma Z; Ji J
    Stem Cells; 2020 Sep; ():. PubMed ID: 32985068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA N6-methyladenosine modification in regulating cancer stem cells and tumor immune microenvironment and its implication for cancer therapy.
    Kumari S; Kumar S; Muthuswamy S
    J Cancer Res Clin Oncol; 2023 Apr; 149(4):1621-1633. PubMed ID: 35796777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications.
    Wang L; Tang Y
    Biomed Pharmacother; 2023 Jul; 163():114846. PubMed ID: 37167725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in crosstalk between N6-methyladenosine (m6A) modification and circular RNAs in cancer.
    Huang X; Guo H; Wang L; Yang L; Shao Z; Zhang W
    Mol Ther Nucleic Acids; 2022 Mar; 27():947-955. PubMed ID: 35211355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of N6-Methyladenosine in the Differentiation of Cancer Stem Cells and Their Fate.
    Xu Y; Liu J; Chen WJ; Ye QQ; Chen WT; Li CL; Wu HT
    Front Cell Dev Biol; 2020; 8():561703. PubMed ID: 33072746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-methyladenosine (m6A) as a regulator of carcinogenesis and drug resistance by targeting epithelial-mesenchymal transition and cancer stem cells.
    Wang C; Danli Ma ; Yu H; Zhuo Z; Ye Z
    Heliyon; 2023 Mar; 9(3):e14001. PubMed ID: 36915498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development.
    Liu S; Chen S; Tang C; Zhao Y; Cui W; Jia L; Wang L
    Front Oncol; 2022; 12():970833. PubMed ID: 36226062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.
    Chen S; Ren H; Zhang X; Chang L; Wang Z; Wu H; Zhang J; Ren J; Zhou L
    J Clin Lab Anal; 2022 Sep; 36(9):e24611. PubMed ID: 35837987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance.
    Lin H; Wang Y; Wang P; Long F; Wang T
    Mol Cancer; 2022 Jul; 21(1):148. PubMed ID: 35843942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. m6A modification of circHPS5 and hepatocellular carcinoma progression through HMGA2 expression.
    Rong D; Wu F; Lu C; Sun G; Shi X; Chen X; Dai Y; Zhong W; Hao X; Zhou J; Xia Y; Tang W; Wang X
    Mol Ther Nucleic Acids; 2021 Dec; 26():637-648. PubMed ID: 34703649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications.
    Wang D; Zhang Y; Li Q; Zhang A; Xu J; Li Y; Li W; Tang L; Yang F; Meng J
    Biomed Pharmacother; 2023 Nov; 167():115477. PubMed ID: 37696088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m6A modification on the fate of colorectal cancer: functions and mechanisms of cell proliferation and tumorigenesis.
    Jiang X; Jin Z; Yang Y; Zheng X; Chen S; Wang S; Zhang X; Qu N
    Front Oncol; 2023; 13():1162300. PubMed ID: 37152066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of circular RNAs and N6-methyladenosine (m6A) modification on cancer biology.
    Zhang G; Hou J; Mei C; Wang X; Wang Y; Wang K
    Biomed Pharmacother; 2023 Mar; 159():114260. PubMed ID: 36657303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia.
    Liu WW; Wang H; Zhu XY
    Biomark Res; 2022 Aug; 10(1):64. PubMed ID: 35999621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-Methyladenosine-Sculpted Regulatory Landscape of Noncoding RNA.
    Zhang Z; Wei W; Wang H; Dong J
    Front Oncol; 2021; 11():743990. PubMed ID: 34722298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging function of N6-methyladenosine in cancer.
    Hong K
    Oncol Lett; 2018 Nov; 16(5):5519-5524. PubMed ID: 30344705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications.
    Qin S; Mao Y; Wang H; Duan Y; Zhao L
    Int J Biol Sci; 2021; 17(11):2718-2736. PubMed ID: 34345203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The m6A reader IGF2BP1 manipulates BUB1B expression to affect malignant behaviors, stem cell properties, and immune resistance of non-small-cell lung cancer stem cells.
    Hu S; Yan X; Bian W; Ni B
    Cytotechnology; 2023 Dec; 75(6):517-532. PubMed ID: 37841956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism.
    Yue SW; Liu HL; Su HF; Luo C; Liang HF; Zhang BX; Zhang W
    Mol Cancer; 2023 Aug; 22(1):137. PubMed ID: 37582735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA Modifications in Cancer Stem Cell Biology.
    Cerneckis J; Cui Q; Liu W; Shi Y
    Cancer Treat Res; 2023; 190():25-47. PubMed ID: 38112998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.